Mithun Vinod Shah

98PUBLICATIONS
279CO-AUTHORS
Haematological tumoursGene and molecular therapyCardiology (incl. cardiovascular diseases)Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (98)

|Sep 18, 2026
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

|Aug 23, 2026
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

|Jul 25, 2026
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients.

|Jul 18, 2026
Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

|Jun 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

|Apr 06, 2026
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.

Saubia Fathima, Lior Rokach, Nour Ghosoun

Pageof 17

Frequent Collaborators

55 joint publications

Mrinal S Patnaik

44 joint publications

Naseema Gangat

43 joint publications

Aref Al-Kali

42 joint publications

Mark R Litzow